Relmada Therapeutics (NASDAQ:RLMD) outlined progress on its lead urology oncology program and reviewed fourth-quarter results during its fourth quarter and full year 2025 earnings call, highlighting ...
Despite warnings from early childhood experts against too much screen time, schools' reliance on educational technology for grade levels as low as transitional kindergarten has grown — and frustrated ...
Jabil (NYSE:JBL) reported fiscal 2026 second-quarter results that exceeded management’s expectations on both revenue and core operating margin, driven primarily by continued strength in Intelligent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results